Pharmacoeconomic review report : Migalastat (Galafold) (Amicus therapeutics) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Drugs--Cost effectiveness.

Drugs.

Physical Description:

1 online resource (30 pages) : illustrations.

Other Title:

Pharmacoeconomic review report Migalastat

Place of Publication:

Ottawa (ON) : CADTH, 2018.

Summary:

Migalastat (Galafold) is indicated for the long-term treatment of adults with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) who have an amenable mutation. The recommended dosage is 123 mg every other day at the same time of day. At the submitted price, migalastat at $1,700 per capsule is $310,250 annually per patient, which is similar to the publicly available prices of IV enzyme replacement therapy (ERT). The indication for migalastat differs with the indication for ERTs, given the requirement for an amenable mutation for migalastat.

Contents:

Abbreviations

Executive Summary

Background

Summary of Identified Limitations and Key Results

Conclusions

Information on the Pharmacoeconomic Submission

Summary of the Manufacturer's PE Submission

Manufacturer's Base case

Summary of Manufacturer's Sensitivity Analyses

Limitations of Manufacturer's Submission

CADTH Common Drug Review Reanalyses

Issues for Consideration

Patient Input

Appendix 1. Cost Comparison

Appendix 2. Summary of Key Outcomes

Appendix 3. Additional Information

Appendix 4. Summary of Other Health Technology Assessment Reviews of Drug

Appendix 5. Reviewer Worksheets

References.

Notes:

Description based on publisher supplied metadata and other sources.

Includes bibliographical references.